Clinical trial / 2014
Extended-release niacin with laropiprant did not reduce major vascular events but increased serious adverse events in high-risk patients on statins.
A randomized trial assigned 25,673 adults with vascular disease receiving background statin therapy to 2 g extended-release niacin plus 40 mg laropiprant daily or matching placebo for a median of 3.9 years. Niacin-laropiprant lowered LDL cholesterol by 10 mg/dL and increased HDL cholesterol by 6 mg/dL compared to placebo, but had no significant effect on major vascular events (13.2% vs. 13.7%; rate ratio 0.96; 95% CI, 0.90 to 1.03; P=0.29). It was associated with significant absolute excesses in serious diabetes disturbances (3.7 percentage points), diabetes diagnoses (1.3 percentage points), and serious gastrointestinal, musculoskeletal, skin, infection, and bleeding adverse events.
- Study type
- Randomized controlled trial
- Who was studied
- 25,673 adults with vascular disease on background statin therapy
- What was measured
- First major vascular event and adverse events
THE PAPER
Effects of extended-release niacin with laropiprant in high-risk patients.
HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J. N Engl J Med, 2014.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.